Trials / No Longer Available
No Longer AvailableNCT05627466
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Expanded Access Program for Magrolimab
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The goal of this expanded access program is to provide rapid access to magrolimab free-of-cost material, to treat patients in the United States suffering from relapsed or refractory acute myeloid leukemia (AML).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Magrolimab | Administered intravenously |
Timeline
- First posted
- 2022-11-25
- Last updated
- 2024-02-15
Source: ClinicalTrials.gov record NCT05627466. Inclusion in this directory is not an endorsement.